BioLineRx Ltd

BioLineRx is a biopharmaceutical company focused on developing therapies in oncology and rare diseases. Its first approved product, APHEXDA (motixafortide), is a novel peptide approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma patients, now commercialized by Ayrmid Pharma (globally, excluding Asia) and Guangzhou Gloria Biosciences (in Asia) under out-licensing agreements. BioLineRx retains rights to develop motixafortide across all solid tumor indications outside of Asia, including pancreatic cancer, where a Phase 2b randomized study is ongoing in collaboration with Regeneron and Columbia University. The company is also advancing GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers, through a collaboration with Hemispherian AS. GLIX1 entered a first-in-human Phase 1/2 clinical trial in April 2026 and holds Orphan Drug Designation from both the FDA and EMA. BioLineRx's strategy centers on in-licensing innovative assets with back-ended, success-based deal structures and funding development through royalties and milestones from its existing partnerships. The company also markets BL-5010, a legacy skin lesion removal product out-licensed to Perrigo for OTC use in Europe. BioLineRx trades on Nasdaq as ADSs, with each ADS representing 600 ordinary shares. Updated May 27, 2026